Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

44 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of canakinumab as a second line biologic after tocilizumab treatment failure in children with systemic juvenile idiopathic arthritis: A single-centre cohort study using routinely collected health data.
Alexeeva E, Krekhova E, Dvoryakovskaya T, Isaeva K, Chomakhidze A, Chistyakova E, Lomakina O, Denisova R, Mamutova A, Fetisova A, Gautier M, Vankova D, Kriulin I, Saygitov R. Alexeeva E, et al. Front Pediatr. 2023 Feb 22;11:1114207. doi: 10.3389/fped.2023.1114207. eCollection 2023. Front Pediatr. 2023. PMID: 36911042 Free PMC article.
Predictors of the response to etanercept in patients with juvenile idiopathic arthritis without systemic manifestations within 12 months: results of an open-label, prospective study conducted at the National Scientific and Practical Center of Children's Health, Russia.
Alexeeva EI, Namazova-Baranova LS, Bzarova TM, Valieva SI, Denisova RV, Sleptsova TV, Isaeva KB, Chomahidze AM, Taibulatov NI, Fetisova AN, Karaseva AV, Baranov AA. Alexeeva EI, et al. Pediatr Rheumatol Online J. 2017 Jun 14;15(1):51. doi: 10.1186/s12969-017-0178-9. Pediatr Rheumatol Online J. 2017. PMID: 28615036 Free PMC article.
Comparative analysis of the etanercept efficacy in children with juvenile idiopathic arthritis under the age of 4 years and children of older age groups using the propensity score matching method.
Alexeeva E, Dvoryakovskaya T, Denisova R, Sleptsova T, Isaeva K, Chomahidze A, Fetisova A, Mamutova A, Alshevskaya A, Gladkikh V, Moskalev A. Alexeeva E, et al. Mod Rheumatol. 2019 Sep;29(5):848-855. doi: 10.1080/14397595.2018.1516329. Epub 2019 Jan 3. Mod Rheumatol. 2019. PMID: 30149747
Efficacy and Safety of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis With and Without Fever at Baseline: Results From an Open-Label, Active-Treatment Extension Study.
Brunner HI, Quartier P, Alexeeva E, Constantin T, Koné-Paut I, Marzan K, Schneider R, Wulffraat NM, Chasnyk V, Tirosh I, Kallinich T, Kuemmerle-Deschner J, Wouters C, Lauwerys B, Nikishina I, Trachana M, Vougiouka O, Martini A, Lovell DJ, Levy J, Vritzali E, Ruperto N; Paediatric Rheumatology International Trials Organisation, the Pediatric Rheumatology Collaborative Study Group. Brunner HI, et al. Among authors: alexeeva e. Arthritis Rheumatol. 2020 Dec;72(12):2147-2158. doi: 10.1002/art.41436. Epub 2020 Oct 31. Arthritis Rheumatol. 2020. PMID: 32648697 Clinical Trial.
Tapering Canakinumab Monotherapy in Patients With Systemic Juvenile Idiopathic Arthritis in Clinical Remission: Results From a Phase IIIb/IV Open-Label, Randomized Study.
Quartier P, Alexeeva E, Constantin T, Chasnyk V, Wulffraat N, Palmblad K, Wouters C, I Brunner H, Marzan K, Schneider R, Horneff G, Martini A, Anton J, Wei X, Slade A, Ruperto N, Abrams K; Paediatric Rheumatology International Trials Organisation and the Pediatric Rheumatology Collaborative Study Group. Quartier P, et al. Among authors: alexeeva e. Arthritis Rheumatol. 2021 Feb;73(2):336-346. doi: 10.1002/art.41488. Epub 2020 Dec 11. Arthritis Rheumatol. 2021. PMID: 32783351 Free PMC article. Clinical Trial.
Development and initial validation of a composite disease activity score for systemic juvenile idiopathic arthritis.
Tibaldi J, Pistorio A, Aldera E, Puzone L, El Miedany Y, Pal P, Giri PP, De H, Khubchandani R, Chavan PP, Vilaiyuk S, Lerkvaleekul B, Yamsuwan J, Sabui TK, Datta P, Pardeo M, Bracaglia C, Sawhney S, Mittal S, Hassan WA, Elderiny GF, Abu-Zaid MH, Eissa M, Sztajnbok F, das Neves Sztajnbok FC, Russo R, Katsicas MM, Cimaz R, Marrani E, Alexeeva E, Dvoryakovskaya TM, Alsuweiti MO, Alzyoud RM, Kostik M, Chikova I, Minoia F, Filocamo G, Farag Y, Lotfy H, Nasef SI, Al-Mayouf SM, Maggio MC, Magalhaes CS, Gallizzi R, Conti G, Shimizu M, Civino A, Felici E, Giancane G, Ruperto N, Consolaro A, Ravelli A. Tibaldi J, et al. Among authors: alexeeva e. Rheumatology (Oxford). 2020 Nov 1;59(11):3505-3514. doi: 10.1093/rheumatology/keaa240. Rheumatology (Oxford). 2020. PMID: 32829413
Early combination therapy with etanercept and methotrexate in JIA patients shortens the time to reach an inactive disease state and remission: results of a double-blind placebo-controlled trial.
Alexeeva E, Horneff G, Dvoryakovskaya T, Denisova R, Nikishina I, Zholobova E, Malievskiy V, Santalova G, Stadler E, Balykova L, Spivakovskiy Y, Kriulin I, Alshevskaya A, Moskalev A. Alexeeva E, et al. Pediatr Rheumatol Online J. 2021 Jan 6;19(1):5. doi: 10.1186/s12969-020-00488-9. Pediatr Rheumatol Online J. 2021. PMID: 33407590 Free PMC article. Clinical Trial.
Treatment of Multisystem Inflammatory Syndrome in Children.
McArdle AJ, Vito O, Patel H, Seaby EG, Shah P, Wilson C, Broderick C, Nijman R, Tremoulet AH, Munblit D, Ulloa-Gutierrez R, Carter MJ, De T, Hoggart C, Whittaker E, Herberg JA, Kaforou M, Cunnington AJ, Levin M; BATS Consortium. McArdle AJ, et al. N Engl J Med. 2021 Jul 1;385(1):11-22. doi: 10.1056/NEJMoa2102968. Epub 2021 Jun 16. N Engl J Med. 2021. PMID: 34133854 Free PMC article.
44 results